高级搜索

培美曲塞联合顺铂治疗骨肉瘤肺转移的临床观察

田聪, 汤丽娜, 李洪涛, 林峰, 沈赞, 闵大六, 姚阳

在线预览 下载 (1.5MB)
田聪, 汤丽娜, 李洪涛, 林峰, 沈赞, 闵大六, 姚阳. 培美曲塞联合顺铂治疗骨肉瘤肺转移的临床观察[J]. 肿瘤防治研究, 2014, 41(11): 1219-1222. DOI: 10.3971/j.issn.1000-8578.2014.11.013
引用本文: 田聪, 汤丽娜, 李洪涛, 林峰, 沈赞, 闵大六, 姚阳. 培美曲塞联合顺铂治疗骨肉瘤肺转移的临床观察[J]. 肿瘤防治研究, 2014, 41(11): 1219-1222. DOI: 10.3971/j.issn.1000-8578.2014.11.013
shu
TIAN Cong, TANG Li'na, LI Hongtao, LIN Feng, SHEN Zan, MIN Daliu, YAO Yang. Clinical Curative Effects of Pemetrexed Combined with Cisplatin in Treatment for Osteosarcoma Patients with Lung Metastasis[J]. Cancer Research on Prevention and Treatment, 2014, 41(11): 1219-1222. DOI: 10.3971/j.issn.1000-8578.2014.11.013
Citation: TIAN Cong, TANG Li'na, LI Hongtao, LIN Feng, SHEN Zan, MIN Daliu, YAO Yang. Clinical Curative Effects of Pemetrexed Combined with Cisplatin in Treatment for Osteosarcoma Patients with Lung Metastasis[J]. Cancer Research on Prevention and Treatment, 2014, 41(11): 1219-1222. DOI: 10.3971/j.issn.1000-8578.2014.11.013
shu

培美曲塞联合顺铂治疗骨肉瘤肺转移的临床观察

  • 1. 215006 苏州，苏州大学医学部研究生院；2. 201999 上海，上海交通大学附属第六人民医院肿瘤内科

基金项目: 国家自然科学基金（81172548,81102038）
详细信息
    作者简介:

    田聪（1987-），女，硕士在读，主要从事骨与软组织肿瘤的综合治疗

    通信作者:

    姚阳，E-mail: yangyao_6@hotmail.com

  • 中图分类号: R738.1

Clinical Curative Effects of Pemetrexed Combined with Cisplatin in Treatment for Osteosarcoma Patients with Lung Metastasis

  • 1.Department of Medical School of Soochow University, Suzhou 215131, China; 2.Department of Oncology, The Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 201999,China

摘要

    摘要
  • 摘要: 目的 观察培美曲塞联合顺铂治疗转移性骨肉瘤患者的有效性和安全性。方法 收集18例一线治疗失败的骨肉瘤肺转移患者，其中男性14例，女性4例，中位年龄20岁，Karnofsky体能状况（KPS）评分≥70。具体方案：培美曲塞500 mg/m2 d1 + 顺铂80~100 mg/m2 d1~2，静脉滴注，每3周重复；化疗2周期后评价疗效及不良反应。结果 18例均可评价疗效，无CR、PR患者，MR 1例，SD 7例，PD 10例，疾病控制率（DCR）为44.4% （8/18），中位无疾病进展时间为9周（95%CI：5～13 周），中位总生存时间为12月（95%CI：9~16月）。治疗后最常见的不良反应为胃肠道反应、贫血、乏力，发生率分别为50.0%、44.4%、38.9%，对症处理后均明显缓解。结论 培美曲塞联合顺铂治疗骨肉瘤肺转移患者具有一定的疗效，不良反应发生率低，耐受性较好。
    Abstract: Objective To evaluate the efficacy and safety of pemetrexed combined with cisplatin for metastatic osteosarcoma patients. Methods We collected 18 osteosarcoma patients with lung metastasis with failed first-line chemotherapy, 18 males and 14 females. Median age was 20 years old, and Karnofsky performance status(KPS) score was ≥70. The patients received pemetrexed 500mg/m2 on day 1 and cisplatin 80-100 mg/m2 on day 1-2 by intravenous infusion, 21 days as a cycle. Efficacy and toxicity were evaluated after 2 cycles. Results Totally 18 patients could be evaluated, with 0 case of CR or PR, 1 case of minimal response(MR), 7 cases of stable disease(SD) and 10 cases of progression disease(PD). Disease control rate was 44.4% (8/18). Median progression-free survival and overall survival time were 9.0 weeks (95% CI: 5-13 weeks) and 12.0 months (95%CI: 9-16 months), respectively. The common adverse effects were digestive tract reaction (50.0%), anemia (44.4%) and fatigue (38.9%), which were apparently relieved after symptomatic treatments. Conclusion Pemetrexed combined with cisplatin have certain efficacy for osteosarcoma patients with lung metastasis, with well tolerance and low incidence of adverse reactions.
    • HTML全文
    • 参考文献(16)
  • [1] Picci P. Osteosarcoma (osteogenic sarcoma)[J]. Orphanet J Rare Dis, 2007, 2:6.
    [2] Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols[J]. J Clin Oncol, 2002, 20(3): 776-90.
    [3] Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children's Research Hospital OS-91 trial[J].J Clin Oncol, 200l, 19 (1): 171-82.
    [4] Lin F, Yue J, Tang LN, et al. Monitoring the plasma concentration of high-dosage of methotrexate during chemotheraphy for osteosarcoma and its clinical significance[J].Zhong Liu,2008,28(5): 440-2.[林峰,岳娟,汤丽娜,等.大剂量甲氨蝶呤 在治疗骨肉瘤中的血药浓度监测及其临床意义[J]. 肿瘤, 2008, 28 (5): 440-2.]
    [5] Hazarika M, White RM, Johnson JR, et al. FDA drug approval summaries: pemetrexed (Alimta)[J]. Oncologist, 2004, 9(5): 48 2-8.
    [6] Cohen MH, Johnson JR, Wang YC, et al. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer[J]. Oncologist, 2005, 10(6): 363-8.
    [7] Kudawara I, Aoki Y, Ueda T, et al. Neoadjuvant and adjuvant chemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: a phase II trial in Japan[J]. J Chemother, 2013, 25(1): 41-8.
    [8] Holmboe L, Andersen AM, Mørkrid L, et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients[J]. Br J Clin Pharmacol, 2012, 73(1): 10 6-14.
    [9] Dupuis C, Mercier C, Yang C, et al. High-dose methotrexate in adults with osteosarcoma: a population pharmacokinetics study and validation of a new limited sampling strategy[J].Anticancer Drugs, 2008, 19(3): 267-73.
    [10] Hartmann JT, Bauer S, Egerer G, et al. Pemetrexed in patients with refractory soft tissue sarcoma: a non-comparative multicenter phase II study of the German Sarcoma Group AIO-STS 005[J]. Invest New Drugs, 2013, 31(1): 167-74.
    [11] Norris RE, Rappaport EF, Adamson PC. Preclinical evaluation of pemetrexed in pediatric solid tumors[J]. Pediatr Blood Cancer, 20 11, 57(7):1233-5.
    [12] Bodmer N, Walters DK, Fuchs B. Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines[J]. Pediatric Blood Cancer, 2008, 50(4): 905-8.
    [13] Malempati S, Nicholson HS, Reid JM, et al. Phase I Trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children’s Oncology Group[J]. J Clin Oncol, 20 07, 25(12):1505-11.
    [14] Warwick AB, Malempati S, Krailo M, et al. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children’s Oncology Group study[J]. Pediatric Blood Cancer, 2013, 60(2): 237-41.
    [15] Duffaud F, Egerer G, Ferrari S, et al. A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma[J]. Eur J Cancer, 2012, 48(4): 564-70.
    [16] Lin LZ, Zhou JX, Zhang EX, et al. Rh-endostatin(endostar) combined with pemetrexed for two recurrent and refractory os t eos a r coma [ J ] . Zhongguo Zhong Liu Lin Chuang, 20 07,34(20):1197-9.[林丽珠,周京旭,张恩欣,等.恩度联合 含培美曲塞方案治疗复发耐药骨肉瘤2例[J].中国肿瘤临 床,2007,34(20):1197-9.]
    • 相关文章
    • 施引文献
    • 资源附件(0)
在线预览 下载 (1.5MB)
计量
  • 文章访问数:  2810
  • HTML全文浏览量:  523
  • PDF下载量:  500
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-12-26
  • 修回日期:  2014-05-12
  • 刊出日期:  2014-11-24

目录

摘要
HTML全文
    参考文献(16)
    相关文章
    施引文献
    资源附件(0)
    Corresponding author: YAO Yang, yangyao_6@hotmail.com

    • 1.Department of Medical School of Soochow University, Suzhou 215131, China; 2.Department of Oncology, The Affiliated Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 201999,China

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：20959454 今日访问：36515

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭